Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

mTOR Signaling in Growth Control and Disease

Target of Rapamycin (TOR) Regulates Growth in Response to Nutritional Signals

Nutrient regulation of mTORC1 at a glance

The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease

mTOR and autophagy: A dynamic relationship governed by nutrients and energy

The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Progress in mTOR study

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Targeting mTOR globally in cancer: thinking beyond rapamycin.

mTOR coordinates protein synthesis, mitochondrial activity and proliferation

Mtor Signaling in Stem and Progenitor Cells

Nutrient sensing and TOR signaling in yeast and mammals

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

The mTORC2 signaling network: targets and cross-talks

Regulation of mTORC1 by Upstream Stimuli

Nuclear mTOR Signaling Orchestrates Transcriptional Programs Underlying Cellular Growth and Metabolism

Targeting the biology of aging with mTOR inhibitors